Core Insights - The FDA has approved the Magstim Horizon 3.0 and Inspire Transcranial Magnetic Stimulation (TMS) Systems for treating major depressive disorder (MDD) in adolescents aged 15-21, providing a non-invasive treatment option [1][2] - Major depression affects over 5 million adolescents in the U.S. annually, with 20% of those aged 12 to 16 experiencing at least one major depressive episode [1][3] - TMS is a non-invasive procedure that stimulates nerve cells in the brain, improving symptoms of MDD without the systemic side effects associated with traditional antidepressants [2][5] Company Insights - Magstim is the only TMS system capable of treating MDD, Anxious Depression, OCD, and Adolescent Depression with a single treatment coil [4] - The company has delivered over 400 million treatment pulses using the Horizon 3.0 system, demonstrating its extensive application in mental health treatment [5] - Magstim has a long history in TMS technology, having developed the first system over 30 years ago, with over 16,000 studies published worldwide citing its stimulators [5] Industry Insights - The approval of TMS for adolescents reflects a growing need for innovative treatment options in mental health, particularly for young patients who may not respond to or prefer not to use antidepressants [2][4] - The WHO emphasizes the importance of addressing untreated depression during adolescence, as it is a leading cause of illness and disability [3] - The advancement in TMS technology aligns with the increasing demand for non-pharmacological treatment methods in mental health care [4]